The FDA has revoked approval of the breast cancer indication for bevacizumab (Avastin; Genetech), saying that studies have not shown enough of a benefit to outweigh the drug's serious and potentially life-threatening side effects.

Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.

to evaluate corneal endothelial cell changes after intravitreal and subconjunctival injection of avastin (bevacizumab) based on specular microscopic findings.  this prospective interventional study was performed on 82 eyes of 82 patients. forty-two cases with ptrygia received a subconjunctival injection of bevacizumab (2.5mg/0.2ml) and 40 diabetic subjects with retinal neovascularization or mac...

we report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. the patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (avastin) via pars plana. after one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform nd: yag...

Evaluation of: Tufail A, Patel PJ, Egan C et al.; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 340, c2459 (2010). The ABC trial is the first multicenter, randomized clinical trial that addresses the safety and efficacy of bevacizumab (Avastin(®), Genentech, Inc., CA, USA) in the treatment of ...

Cancer cells secrete VEGF, which plays a key role in their growth, invasion, extravasation and metastasis. Direct cancer cell-endothelial cell interaction, mediated by gap junctions, is of critical importance in the extravasation process. In this study, we evaluated avastin (Av), an anti-VEGF antibody; and oleamide (OL), a gap junction inhibitor, using MDA-MB-231 human breast cancer cells in vi...

Vascular endothelial growth factor (VEGF) is an important stimulator for angiogenesis in solid tumors. Blocking VEGF activity is an effective therapeutic strategy to inhibit tumor growth and metastasis. Avastin, a humanized monoclonal antibody recognizes VEGF, has been approved by the US Food and Drug Administration. To generate potential VEGF-recognizing antibodies with better tumor regression...

Adding Avastin (bevacizumab) to chemotherapy for early stage colon cancer didn’t reduce the risk that cancer would return. In fact, preliminary results of the AVANT trial found that chemotherapy alone worked better in preventing recurrences of stage III and high-risk stage II colon cancer, according to a news release from Roche, who were the sponsors of the international clinical trial. This is...